July 14, 2020: Based on the data discussed today, it is difficult to determine how well Belantamab Mafodotin works and whether its effect is clinically meaningful. To approve a treatment for which the benefits do not clearly outweigh the risks creates additional risk for those who are already suffering.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR’s Comments on USPSTF’s Draft Recommendation Statement for Tobacco Smoking Cessation in Adults, Including Pregnant Persons
We strongly agree with the USPSTF’s recommendation that all physicians ask their adult patients and pregnant patients about their tobacco use. However, encourage the USPSTF to consider two suggestions that would strengthen this recommendation.
Read More »NCHR’s Testimony to FDA on Pediatric Development Plans for Oncology Indications
When evaluating drugs for pediatric use, doses must be scrutinized cautiously for children of different ages and weights. Even when there are likely benefits for children on average, it is important to minimize risks whenever possible by determining which children are most and least likely to benefit.
Read More »NCHR’s Comments on CPSC’s Proposed Safety Standards for Crib Bumpers/Liners
We strongly urge the CPSC to ban the sale of crib bumpers and liners. The known risks of crib bumpers far outweigh any potential benefits. While these products have not demonstrated any clear benefits, there is evidence that they can cause serious injury, including death.
Read More »NCHR’s Comments on USPSTF’s Draft Research Plan for Cardiovascular Disease Prevention
June 8, 2020. We support the US Preventive Services Task Force’s efforts to update recommendations based on new scientific evidence.
Read More »